Research Use Only Important Legal Notice Used solely for in vitro experiments and cannot be: Used in clinical trials involving humans Administered to humans as part of an experiment or investigation, Supplied to another party for human investigational use.
Just as importantly, the addition of extra ingredients creates a formulation that differs from the branded products, which compounders may use as a legal justification to avoid producing an outright copy of a brand-name drug.Recall Initiation Date: July 18, 2025Link: FDA Enforcement Report Semaglutide Company: Boothwyn Pharmacy, LLC (licensed compounding pharmacy)Location: Kennett Square, PennsylvaniaScope: Semaglutide, 2.5 mg/mL injection: .8 mL (186 vials), 2 mL (642 vials), 4 mL (648 vials)Drug Description: Treats type 2 diabetes and obesityRecall Reason: Subpotent drugs (which means they less than the specified amount of active ingredient)Recall Initiation Date: July 9, 2025Link: FDA Enforcement Report Semaglutide, Semaglutide/Cyanocobalamin, Tirzepatide, Tirzepatide/Cyanocobalamin Company: Thrive Health and Wellness, LLC, dba Thrive Health Solutions (Colorado)Location: Englewood, ColoradoScope: Semaglutide: 5 mg/mL (164 pre-filled syringes)
These findings point to a dual mechanism of action: preservation of rod photoreceptors and functional support to inner retinal circuits, underlying the observed rescue of visual signaling
The consequences of dosing errors range from mild to serious
